Winning the War Against HIV/AIDS
The evolution of HIV/AIDS treatment is nothing short of remarkable. Innovative treatments have dramatically transformed how the disease is treated to help patients live healthier, fuller lives.READ MORE
We are America's Biopharmaceutical Companies, driven to discover the next lifesaving breakthrough and dedicated to ending the burdens of disease. And with new, innovative medicines on the horizon, we're closer than ever to reaching our goal.READ MORE
WELCOME TO THE NEW ERA OF MEDICINE
Finding lifesaving treatments is our life’s work—the work of the 140,000 biopharmaceutical researchers who boldly leap into the unknown to pioneer tomorrow’s breakthrough cures. It’s also the work of millions of patients who fight against whatever obstacles they face.
Can We Afford the New Era of Medicine?
Innovative treatments require innovative partnerships. America's Biopharmaceutical Companies and insurers are partnering to get the right medicine in the hands of patients who need them.READ MORE
We Cannot Take Progress for Granted
We are in a new era of medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we must not take this progress for granted.READ MORE
Migraine: More than Just a Bad Headache
Migraine is a debilitating neurological disease that is often misunderstood by those who do not suffer symptoms, according to the Migraine Impact Report, a new survey recently released by Eli Lilly and Company and conducted by Nielsen.READ MORE
Tackling Neurological Disorders in New Ways
Chronic pain. Alzheimer's disease. Multiple Sclerosis. Brain tumors. These are some of the most well-known and prevalent diseases afflicting the more than 100 million Americans who are impacted by a neurological disorder.READ MORE
Together, we fight disease
I believe a cure is within reach.
Outsmarting Breast Cancer
Thanks to advances in modern medicine, there has been significant progress for breast cancer patients in the last decade. Groundbreaking innovations in personalized medicine are changing the course of treatment to create potential first-in-class therapies and the promise of a cancer-free future.LEARN MORE
The work I do can save lives.
Lung Cancer Gets Personal
Lung cancer counts for 25% of all cancer deaths in the U.S. That's why every day, researchers search relentlessly to unearth more innovative breakthroughs. Thanks to their dedication, there are now 240 immuno-oncology treatments in development to give hope and a future for patients with cancer.LEARN MORE
Transplantation in the beginning was simply life-saving. Now...it is life-giving, all thanks to...anti-rejection drugs.
At the Heart of Transplantation
Transplant researchers aren't missing a beat when it comes to pioneering treatments to prevent transplant rejection and the recurrence of the original disease. Their latest findings are helping patients get a second chance at life.LEARN MORE
At the core of innovative research and development of lifesaving medicines is our single vision: a world without illness. With the pipeline of promising new treatments on the horizon, we're closer than ever to reaching our goal.
These diseases occur when the immune system attacks the body’s own tissues. Learn about advancements in the field.
Heart disease is the leading cause of death in the U.S. Learn how researchers are making advances with the latest treatments.
Cancer is the second leading cause of death in the U.S., but death rates are declining. See how researchers are fighting back.
This is an age of promise – fueled by the drive to discover and a dedication to a future without illness. As researchers relentlessly pursue the next breakthrough, they put us closer than ever to take down disease.
Gene function provides crucial insights about the immune system. Learn how genomics has transformed medicine.
Immunotherapy empowers the immune system to attack diseased cells. See how researchers harness this power.
Researchers are transforming scientific discoveries into lifesaving medicines. Explore the latest innovations.